Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
-
Published:2024-01-27
Issue:1
Volume:108
Page:
-
ISSN:0175-7598
-
Container-title:Applied Microbiology and Biotechnology
-
language:en
-
Short-container-title:Appl Microbiol Biotechnol
Author:
Cervantes-Torres Jacquelynne, Cabello-Gutiérrez Carlos, Ayón-Núñez Dolores-Adriana, Soldevila Gloria, Olguin-Alor Roxana, Diaz Georgina, Acero Gonzalo, Segura-Velázquez René, Huerta Leonor, Gracia-Mora Isabel, Cobos Laura, Pérez-Tapia Mayra, Almagro Juan C., Suárez-Güemes Francisco, Bobes Raúl J., Fragoso Gladis, Sciutto EddaORCID, Laclette Juan Pedro
Abstract
Abstract
Several COVID-19 vaccines use adenovirus vectors to deliver the SARS-CoV-2 spike (S) protein. Immunization with these vaccines promotes immunity against the S protein, but against also the adenovirus itself. This could interfere with the entry of the vaccine into the cell, reducing its efficacy. Herein, we evaluate the efficiency of an adenovirus-vectored vaccine (chimpanzee ChAdOx1 adenovirus, AZD1222) in boosting the specific immunity compared to that induced by a recombinant receptor-binding domain (RBD)-based vaccine without viral vector. Mice immunized with the AZD1222 human vaccine were given a booster 6 months later, with either the homologous vaccine or a recombinant vaccine based on RBD of the delta variant, which was prevalent at the start of this study. A significant increase in anti-RBD antibody levels was observed in rRBD-boosted mice (31–61%) compared to those receiving two doses of AZD1222 (0%). Significantly higher rates of PepMix™- or RBD-elicited proliferation were also observed in IFNγ-producing CD4 and CD8 cells from mice boosted with one or two doses of RBD, respectively. The lower efficiency of the ChAdOx1-S vaccine in boosting specific immunity could be the result of a pre-existing anti-vector immunity, induced by increased levels of anti-adenovirus antibodies found both in mice and humans. Taken together, these results point to the importance of avoiding the recurrent use of the same adenovirus vector in individuals with immunity and memory against them. It also illustrates the disadvantages of ChAdOx1 adenovirus-vectored vaccine with respect to recombinant protein vaccines, which can be used without restriction in vaccine-booster programs.
Key points
• ChAdOx1 adenovirus vaccine (AZD1222) may not be effective in boosting anti-SARS-CoV-2 immunity
• A recombinant RBD protein vaccine is effective in boosting anti-SARS-CoV-2 immunity in mice
• Antibodies elicited by the rRBD-delta vaccine persisted for up to 3 months in mice
Funder
UNAM Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica UNAM Instituto de Investigaciones Biomedicas
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,General Medicine,Biotechnology
Reference45 articles.
1. Aguilar-Guerra EM, Fajardo-Díaz C, Gorry (2021) Cuba’s National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED). MEDICC Rev 23(3–4):9–14. https://doi.org/10.37757/MR2021.V23.N3.3 2. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O’Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH (2022) Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med 386(11):1046–1057. https://doi.org/10.1056/NEJMoa2116414 3. Ayón-Núñez DA, Cervantes-Torres J, Cabello-Gutiérrez C, Rosales-Mendoza S, Rios-Valencia D, Huerta L, Bobes RJ, Carrero JC, Segura-Velázquez R, Fierro NA, Hernández M, Zúñiga-Ramos J, Gamba G, Cárdenas G, Frías-Jiménez E, Herrera LA, Fragoso G, Sciutto E, Suárez-Güemes F, Laclette JP (2022) An RBD-based diagnostic method useful for the surveillance of protective immunity against SARS-CoV-2 in the population. Diagnostics (Basel) 12(7):1629. https://doi.org/10.3390/diagnostics12071629 4. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O’Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4(115):115ra1. https://doi.org/10.1126/scitranslmed.3003155 5. Barrett et al, 2021Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, Verheul MK, Aley PK, Angus B, Bellamy D, Berrie E, Bibi S, Bittaye M, Carroll MW, Cavell B, Clutterbuck EA, Edwards N, Flaxman A, Fuskova M, Gorringe A, Hallis B, Kerridge S, Lawrie AM, Linder A, Liu X, Madhavan M, Makinson R, Mellors J, Minassian A, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy MN, Robinson H, Rollier CS, Song R, Snape MD, Tarrant R, Taylor S, Thomas KM, Voysey M, Watson MEE, Wright D, Douglas AD, Green CM, Hill AVS, Lambe T, Gilbert S, Pollard AJ; Oxford COVID Vaccine Trial Group (2021) Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med 27(2):279-288. https://doi.org/10.1038/s41591-020-01179-4
|
|